Sabra Health Care REIT (SBRA) Cash & Equivalents (2010 - 2026)

Sabra Health Care REIT's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 10.84% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 10.84% increase from a year earlier, with the FY2025 full-year figure at $71.5 million, up 18.31% from the prior year.
• Cash & Equivalents fell to $6.9 million in Q1 2026 per SBRA's latest filing, from $71.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $200.6 million in Q3 2025 and bottomed at $5.4 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $33.3 million (2023), against an average of $44.5 million.
• Across the five-year window, Cash & Equivalents tumbled 89.05% in 2023 and surged 3259.04% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $49.3 million in 2022, then tumbled by 89.05% to $5.4 million in 2023, then surged by 1019.78% to $60.5 million in 2024, then increased by 18.31% to $71.5 million in 2025, then slumped by 90.33% to $6.9 million in 2026.
• Per Business Quant, the three latest SBRA Cash & Equivalents figures stand at $6.9 million (Q1 2026), $71.5 million (Q4 2025), and $200.6 million (Q3 2025).